KRAIG BIOCRAFT LABORATORIES, INC.: 10-Q filed 2023-11-13
What KRAIG BIOCRAFT LABORATORIES, INC. reported in its quarterly report filed 2023-11-13 (fiscal Q3 2023): 31 published measures, 90 facts as tagged in accession 0001493152-23-040575.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2023-11-13
- Fiscal period
- fiscal Q3 2023
- Accession
- 0001493152-23-040575 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All KRAIG BIOCRAFT LABORATORIES, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 3,626,734 | USD | |
| At 2022-12-31 | 4,570,920 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 8,625,267 | USD | |
| At 2022-12-31 | 8,092,780 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -4,998,533 | USD | |
| At 2023-06-30 | -4,510,651 | USD | |
| At 2022-12-31 | -3,521,860 | USD | |
| At 2022-09-30 | -3,786,099 | USD | |
| At 2022-06-30 | -3,774,804 | USD | |
| At 2021-12-31 | -5,295,875 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 2,894,555 | USD | |
| At 2022-12-31 | 3,862,716 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -549,273 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -1,705,146 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -810,356 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -2,895,167 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -916,762 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -1,445,593 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 6,399 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -45,000 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 3,414,864 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -6,399 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -48,362,146 | USD | |
| At 2022-12-31 | -46,657,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 1,033,374,219 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 1,032,946,226 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 976,587,869 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 960,027,786 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 1,033,374,219 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 1,032,946,226 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 976,587,869 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 960,027,786 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 0 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | 0 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | 0 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | 0 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 0 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | 0 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | 0 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | 0 | USD/shares | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 74,218 | USD | |
| At 2022-12-31 | 87,861 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -459,445 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -1,426,687 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -525,280 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -1,607,658 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 2,999,777 | USD | |
| At 2022-12-31 | 3,983,441 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 8,570,531 | USD | |
| At 2022-12-31 | 8,072,083 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 459,445 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 1,426,687 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 525,280 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 1,607,658 | USD | 273 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 6,580 | USD | |
| At 2022-12-31 | 6,580 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 39,129 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 165,256 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 62,118 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 139,491 | USD | 273 |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 10,963,202 | USD | |
| At 2022-12-31 | 10,834,729 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 107,444 | USD | |
| At 2022-12-31 | 58,849 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 107,444 | USD | |
| At 2022-12-31 | 59,897 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 187,896 | USD | |
| At 2022-12-31 | 167,854 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -549,273 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -1,705,146 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -810,356 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -2,895,167 | USD | 273 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -562,294 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -1,705,146 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -810,356 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -2,895,167 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 224,687 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 656,457 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 207,172 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 632,610 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 7,285 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 20,042 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 6,716 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 21,437 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -89,828 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -278,459 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -285,076 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -1,287,509 | USD | 273 |
Operating lease payments
Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 40,802 | USD | 273 |
| 2022-01-01 to 2022-12-31 | 51,344 | USD | 365 |
Inspect the source
- Entity
- KRAIG BIOCRAFT LABORATORIES, INC. / CIK 0001413119
- Captured
- 2026-09-20T08:02:08.774Z
- SEC response SHA-256
920795b2181369f3ae04be68b2de22ae3d9ee7808a72922b976f9dc124464bc6
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001413119.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))